Aldagen news from FierceBiotech
NewsEarly IPO at Aldagen leaves analysts wondering
A pair of analysts has taken a cautious attitude toward Aldagen's plans for an $80 million IPO. The stem-cell company has no Read more...
Elixir drops IPO, Aldagen launches IPO
Elixir Pharmaceuticals has dropped its bid for an $86 million IPO, saying that Read more...
Aldagen gets $18.4M in fourth round
With the help of Intersouth Partners, Tullis-Dickerson, Harbert Venture Partners and The Aurora Funds, stem cell technology company Aldagen has closed an $18.4 million fourth round of funding. The Read more...
Aldagen adds $9M in new venture funds
Durham, NC-based Aldagen has added $9 million in new money for its third round, bringing total investment in the Series C to $23 million. That money will be put to use developing new stem cell Read more...
| Press ReleasesPRESS RELEASE: Aldagen Raises Additional $9 Million, Increasing Series C Financing to $23 Million Aldagen Raises Additional $9 Million, Increasing Series C Financing to $23 Million DURHAM, NC -- Sep 13, 2007 -- Aldagen, Inc., a biotechnology company advancing a pipeline of clinical stage Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets